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Abstract
Introduction: Sepsis is a clinical syndrome associated with a severe systemic inflammation induced by infection.
Although different anti-microbial drugs have been used as treatments, morbidity and mortality rates remain high.
Mesenchymal stem cells (MSCs) derived from the bone marrow have demonstrated a partial protective effect in
sepsis. Menstrual derived MSCs (MenSCs) emerge as an attractive candidate because they present important
advantages over other sources, including improved proliferation rates and paracrine response under specific stress
conditions. Here, we evaluate their therapeutic effect in a polymicrobial severe sepsis model.
Methods: The antimicrobial activity of MenSCs was determined in vitro through direct and indirect bacterial growth
assays and the measurement of the expression levels of different antimicrobial peptides (AMPs) by quantitative
reverse transcription-polymerase chain reaction. The therapeutic effect of MenSCs was determined in the cecal
ligation and puncture (CLP) mouse model. Mice were then treated with antibiotics (AB) or MenSCs alone or in
combination. The survival rates and histological and biochemical parameters were evaluated, and the systemic
levels of pro- and anti-inflammatory cytokines as well as the response of specific lymphocyte subsets were
determined by flow cytometry.
Results: MenSCs exerted an important antimicrobial effect in vitro, mediated by a higher expression of the AMP-
hepcidin. In the CLP mouse model, MenSCs in synergy with AB (a) improved the survival rate (95 %) in comparison
with saline (6 %), AB (73 %), and MenSCs alone (48 %) groups; (b) enhanced bacterial clearance in the peritoneal
fluids and blood; (c) reduced organ injuries evaluated by lower concentrations of the liver enzymes alanine
aminotransferase and aspartate aminotransferase; and (d) modulated the inflammatory response through reduction
of pro- and anti-inflammatory cytokines without significant loss of T and B lymphocytes.
Conclusions: We conclude that MenSCs in combination with AB enhance survival in CLP-induced sepsis by acting
on multiples targets. MenSCs thus constitute a feasible approach for the future clinical treatment of sepsis.
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Introduction
Sepsis is a severe medical condition which ranks among
the top 10 causes of death worldwide and has perman-
ently high incidence rates [1, 2]. Sepsis is caused by an
infection and involves complex interactions between the
pathogenic agent and the host immune cells, character-
ized by a systemic inflammatory state [3]. Although the
role of the immune response is crucial to fight infection,
it is also responsible for the inflammatory tissue infiltra-
tion and severe organ damage, both hallmarks of sepsis
[4]. Recent evidence suggests that the modulation of
pro- and anti-inflammatory factors contributes to the
suppression of immune effector cells that induce the
systemic inflammatory response and tissue damage in
sepsis [3, 5, 6].
Mesenchymal stem cells (MSCs) are a subpopulation
of multipotent cells that may be isolated from various
adult tissues and organs [7]. In recent years, MSCs have
been described as a novel therapeutic strategy for the
treatment of diseases related with inflammation and tis-
sue injury because they are potent modulators of im-
mune system with the ability to regulate both the innate
and adaptive immune response [1, 8, 9]. Several studies
demonstrate that the protective role of MSCs in sepsis
may be attributed essentially to the soluble paracrine
factors released by these cells, such as interleukin-10
(IL-10) [10], prostaglandin E2 (PGE2) [3], tumor necrosis
factor-alpha (TNF-α)-stimulated gene/protein 6 [11],
and IL-6 [12]. In addition, another study ascribes the
therapeutic effect of MSCs in sepsis to direct anti-
bacterial activity mediated by the secretion of the anti-
microbial peptide LL37/hCAP18 [13]. In all preclinical
models, therapy with MSCs showed important thera-
peutic advantages associated with an increase in survival
time, a decrease in the levels of biomarkers associated
with organ injury and the bacterial loads in different or-
gans and biological fluids, and modulation of the im-
mune response [3, 10, 14–16].
Currently, most studies related to MSC therapy in in-
flammatory and tissue damage have focused on MSCs
derived from bone marrow (BMSCs) or adipose tissue
(AT-MSCs) [5, 10, 13, 15, 16], mainly because these two
sources of MSCs have been well characterized and share
immunomodulatory properties [16, 17]. However, from a
clinical point of view, large amounts of MSCs must be
isolated and expanded at low culture passages to obtain
the required number of cells for therapeutic application.
It should also be considered that in some cases multiple
administrations are necessary to reach therapeutic effect.
Because of this, the study of new sources of MSCs re-
solving these issues could be an important advantage for
the treatment of sepsis, and the comparison between
MSCs from different tissues will contribute to select the
best source for this application. In this regard, MSCs
derived from menstrual fluid (MenSCs) emerge as an at-
tractive alternative of cell therapy since they are isolated
in a non-invasive manner with the possibility of period-
ical collections from the same donor, ensuring high
amounts of cells at low culture passages and from the
same genetic background [18, 19].
In the present study, we assessed the therapeutic effect
of MenSC therapy in an animal model of severe sepsis
induced by cecal ligation and puncture (CLP), the main
model for polymicrobial human sepsis [20]. We evalu-
ated the antimicrobial activity of MenSCs in vitro and
assessed the expression of different antimicrobial pep-
tides (AMPs) that could be involved in the anti-bacterial
effect. In addition, we studied the capacity of the
MenSCs to reduce the systemic inflammatory state and
organ dysfunction through the modulation of the im-
mune response and expression of tissue protective/
regenerative factors. Moreover, we compared the
therapeutic effect of MenSCs and their synergy with
antibiotic treatment, considered as the first-line ther-
apy for sepsis.
Methods
Menstrual fluid and bone marrow samples
After informed consent from the donors and ethical
revision and approval from the ethics committees of
Universidad de los Andes and Cells for Cells, men-
strual fluids were collected from four healthy donors
from 24 to 38 years old and bone marrow from three
hip surgery patients from 60 to 72 years to old as de-
scribed previously [19].
Cell culture
MSCs were isolated as described previously [19]. In
brief, MSCs were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) (Invitrogen, part of Thermo Fisher
Scientific, Waltham, MA, USA) supplemented with 10 %
fetal bovine serum (FBS) (Gibco, Carlsbad, CA, USA),
1 % penicillin–streptomycin (Invitrogen), and 1 % L-
glutamine (Invitrogen). Cells were cultured at 37 °C
with 5 % CO2, routinely tested for mycoplasma (EZ-
PCR Mycoplasma test kit; Biological Industries, Israel
Beit-Haemek Ltd, Kibbutz Beit-Haemek, Israel) and
cryopreserved in low passage (<3) until use. All cells
were evaluated in their capacity to differentiate to adipo-
cytes, osteocytes, and chondrocytes by using the StemPro
Differentiation Kits (Gibco, Carlsbad, CA, USA) in ac-
cordance with the instruction of the manufacturer. Immu-
nophenotyping was performed by fluorescence-activated
cell sorting (FACS) by using a FACSCanto II cytometer
(BD Biosciences, San Jose, CA, USA) after staining with
monoclonal antibodies CD105, CD90, CD73, CD44, HLA-
DR, CD34, and CD45 (all from BD Pharmingen, San Jose,
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CA, USA) by using standard protocol. All experiments
were performed by using cells in passage 4–8.
Antimicrobial assay
Assessments of bacterial growth inhibition were per-
formed as direct and indirect assays. Bacteria were iso-
lated from mouse feces. For this, freshly harvested fecal
material was diluted in 10 ml of sterile phosphate-
buffered saline (PBS) and filtered through a 70-μm Cell
Strainer (BD Falcon, Franklin Lakes, NJ, USA). Colony-
forming unit (CFU) concentration was calculated by
counting colonies plated on blood-agar plates after over-
night incubation at 37 °C.
For direct inhibition assays, MSCs cultured in 24-well
plates (2 × 105 cells per well) in DMEM supplemented
with 5 % FBS and 1 % L-glutamine were infected with
300 CFUs of a mix of bacteria and incubated for 6 or
24 hours at 37 °C with 5 % CO2 (normoxia) or 24 hours
at 37 °C with 1 % O2 (hypoxia). Aliquots of the culture
medium were taken from each well, serially diluted with
sterile PBS, and plated on blood-agar plates. Colonies
were counted after overnight incubation at 37 °C. Anti-
microbial activity of MSCs conditioned medium (CM)
(non-stimulated CM condition) or from the co-culture
above (stimulated CM condition) was tested as described
previously with slight modifications [13]. Briefly,
MenSCs CM and BMSCs CM were collected, and the
bacterial fraction was removed by passing the CM
through a 0.22-μm filter (EdLab, New York, NY, USA).
The filtered CM was centrifuged at 13,200 revolutions
per minute for 10 minutes, and multiple freezing and
thawing cycles were then performed (to eliminate any
residual bacterial contamination). Prior to the experi-
ments, samples were thawed on ice, and aliquots of
90 μl of the CM were transferred to a 96-well plate, in-
oculated with 100 CFUs of bacterial mix (in 10 μl of
PBS), and incubated for 16 hours at 37 °C. CFUs were
then counted as described earlier.
mRNA expression
Total RNAs was extracted by using the RNeasy kit
(Qiagen, Marseille, France) in MSCs in basal condition
or previously stimulated with 300 CFUs of bacterial mix.
RNA (2 μg) was then reverse-transcribed by using the
M-MLV enzyme (Fisher Scientific, Illkirch, France). The
real-time quantitative polymerase chain reaction (PCR)
was performed by using Stratagene Mx3000P (Agilent
Technologies, Santa Clara, CA, USA) with the following
forward (F) and reverse (R) primers: hBD-1-F primer:
5ʹ-GCCTCAGGTGGTAACTTTCTCA-3ʹ, hBD-1-R pri-
mer: 5ʹ-GATCGGGCAGGCAGAATAGAG-3ʹ; hBD-2-F:
5ʹ-GGAAGAAATGTCGCAGCCAAG-3ʹ, hBD-2-R: 5ʹ- C
GATTCAGTAAGCTCTCATCCCAT-3ʹ; hBD-3-F: 5ʹ- TT
ATTGCAGAGTCAGAGGCGG -3ʹ, hBD-3-R: 5ʹ-TTTC
TTCGGCAGCATTTTCGG-3ʹ; hepcidin-F: 5ʹ- CCCATG
TTCCAGAGGCGAAG-3ʹ, hepcidin-R: 5ʹ-CTTGCAGCA
CATCCCACACT-3ʹ. For LL-37 peptide mRNA quantifi-
cation was determined by TaqMan gene expression assay
(ID Hs00189038_m1; Applied Biosystems, Waltham, MA,
USA). All values were normalized to either GAPDH
(GAPDH-F: 5ʹ-GGTCTCCTCTGACTTGAACA-3ʹ, G
APDH-R: 5ʹ-GTGAGGGTCTCTCTCTTCCT-3ʹ) or β2M
housekeeping gene (ID Hs00984230_m1; Applied Biosys-
tems) and expressed as relative expression or fold change
using the 2−ΔCT formula [21].
Preparation of conditioned media-derived MenSCs
MenSCs were cultured in normal medium until 80 %
confluence was reached. After three washes with PBS,
cells were cultured in serum-free DMEM supplemented
with 1 % penicillin-streptomycin and 1 % L-glutamine at
37 °C with 5 % CO2. After 72 hours post-culture, the
supernatant was collected. The cellular debris were re-
moved by centrifugation at 500 × g for 5 minutes at
room temperature (RT). The supernatant was concen-
trated approximately 25- to 30-fold by ultrafiltration
using Amicon Ultra centrifugal filters (Merck Millipore,
Tullagreen, Ireland) with a membrane NMWL of 3 kDa
in accordance with the instructions of the manufacturer.
The concentrated medium was sterilized by filtration
through a 0.22-μm syringe filter (Membrane Solutions
LLC, Dallas, TX, USA), and the protein concentration
was determined by Bradford protein assay (Bio-Rad La-
boratories, Hercules, CA, USA). The mean protein con-
centration was 0.3 ± 0.2 μg/ul. Equal volumes of serum-
free DMEM but without cells were used under the same
conditions and served as negative control.
Polymicrobial CLP-induced sepsis
In vivo studies were performed at the Universidad de los
Andes-Cells for Cells Animal Facility (Santiago, Chile) in
accordance with the institutional guidelines for the care
and use of laboratory animals in research, revised and
approved by the Institutional Ethical Committee for ani-
mal experimentation. C57BL6/j mice (8 to 12 weeks old;
Jackson Laboratories, Bar Harbor, ME, USA) received ad
libitum access to food and water during the whole
experimental procedure. CLP-induced sepsis was per-
formed as described previously [20] with some modifica-
tions. Briefly, mice were anesthetized with inhaled
Sevofluorane (Baxter, Guayama, Puerto Rico) by using
an anesthetic vaporizer. After a 1-cm incision was per-
formed, the cecum was exposed and ligated in the mid-
dle portion with 5–0 dafilon suture (Braun, Rubi, Spain),
punctured once with an 18-gauge needle (in order to in-
duce high-grade sepsis), and returned to the peritoneal
cavity. The abdominal incision was sutured with catgut
5–0 (Braun, Bogota, Colombia), and the skin was closed
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with Histoacryl (Braun). In sham-operated mice, the
cecum was exposed and ligated but not punctured. Im-
mediately after the CLP procedure, all animals received
pre-warmed fluid resuscitation with 50 ml/kg saline fluid
by subcutaneous injection.
Treatment of CLP-induced sepsis mice with MSCs and
CM-derived MSCs
Three hours after CLP-induced sepsis, mice were random-
ized and distributed into different experimental groups to
receive single injections of saline (vehicle) (n = 16), antibi-
otics (AB) (n = 22), MenSCs (n = 21), MenSCs + AB (n =
22), MenSC CM (n = 16), or MenSC CM+AB (n = 22).
MenSCs (7.5 × 105 cells/mice) and MenSC CM (70 μg/
300 μl) were inoculated via intra-peritoneal or intra-
venous injection, respectively, alone or with Enrofloxacin
5 mg/kg (Centrovet, Santiago, Chile). For Kaplan-Meier
survival curves, animals were assessed after CLP-induced
sepsis every 12 hours for 4 days. Fluid resuscitation and
antibiotic therapy were administered by subcutaneous in-
jections immediately after the CLP procedure and re-
peated every 24 hours for 4 days. For the evaluation of the
therapeutic effect, animals were sacrificed at 24–40 hours
after CLP-induced sepsis, and total blood was collected by
cardiac puncture for measurement of hematological and
biochemical parameters and cytokine levels. The periton-
eal cavity was washed, and lavage fluid was collected to
determine the bacterial CFUs as previously described [22].
Liver, kidney, and lungs were removed, fixed in 10 % for-
malin solution, and embedded in paraffin by standard
methods. Samples were cut into 5-μm sections and
stained with hematoxylin and eosin in accordance with
standard protocols.
Biodistribution of MenSCs injected in septic mice
At 24 hours post-CLP procedures, 107 MenSCs were la-
beled with PKH26 (Sigma-Aldrich, St. Louis, MO, USA)
in accordance with the protocol of the manufacturer. La-
beling efficiency was 95 % as validated by flow cytometry.
Labelled MenSCs (2 × 106 cells/mouse) were resuspended
in 250 μl of PBS and injected intraperitoneally. Animals
were euthanized at 24 hours post-injection, and different
organs and fluids, including the spleen, heart, kidneys,
lungs, liver, and intraperitoneal fluid, were recovered and
incubated at 37 °C for 30 minutes with 250 U/ml of colla-
genase II and IV (Gibco). The single-cell suspensions ob-
tained were resuspended into 400 μl of cytometry buffer
(PBS 1×, bovine serum albumin (BSA) 0.2 %, sodium azide
0.01 %) and then analyzed by flow cytometry.
Bacterial numbers in blood, peritoneal cavity, and spleen
in CLP-induced sepsis
Total blood, peritoneal fluid, and homogenized spleen in
sterile saline were plated in a 10-fold dilution on blood-
agar plates and incubated at 37 °C overnight, and the
number of CFUs was determined.
Cytokine multiplex array evaluation in CLP mice
The levels of inflammatory cytokines—monocyte chemo-
attractant protein-1 (MCP-1), TNF-α, IL-6, and IL-8—in
CLP mice serum samples were determined by using a
commercial BD™ Cytometric Bead Array Mouse Inflam-
mation Kit (BD Biosciences Pharmingen, San Diego, CA,
USA) in accordance with the instructions of the manufac-
turer. Analysis was carried out by flow cytometry, and the
concentration (in picograms per milliliter) was determined
by using FCAP Array software (BD Biosciences). The pa-
rameters were determined 24 and 40 hours after CLP
surgery.
Blood biochemical analysis in CLP mice
Plasma levels of blood urea nitrogen (BUN), bilirubin, ala-
nine aminotransferase (ALT), aspartate aminotransferase
(AST), alkaline phosphatase (ALP), albumin, amylase, and
glucose were evaluated by using the Piccolo Xpress™
Chemistry Analyzer (Abaxis, Union City, CA, USA) in ac-
cordance with the instructions of the manufacturer. Serum
creatinine was determined by using a commercial kit
(Valtek Diagnostics, Santiago, Chile) in accordance with
the instructions of the manufacturer.
Lymphocyte subset analysis by FACS
Blood was collected by intracardiac puncture with EDTA
as anticoagulant. The red blood cells were lysed with
ACK Lysing Buffer (Gibco) in accordance with the in-
structions of the manufacturer. The collected cells were
resuspended in 100 μl of FACS buffer (PBS 1×, 0.2 %
BSA, 0.01 % sodium azide) and incubated for 20 minutes
at 4 °C with the appropriate fluorescently labeled mono-
clonal antibody directed against lymphocyte surface
markers (BD Biosciences), washed and resuspended in
FACS buffer, and analyzed by the FACS Canto II cyt-
ometer by using the FACS Diva software (BD Biosci-
ences). The viability was determined by using a LIVE/
DEAD®Fixable dead cell stain kit (Invitrogen) in accord-
ance with the protocol of the manufacturer. Approxi-
mately 20,000 gated events were assessed to determine the
percentage of each subset: total lymphocytes (CD3+/APC),
CD4+ T lymphocytes (CD3+ APC, CD4+/PE), CD8+ T
lymphocytes (CD3+/APC, CD8+/FITC), and total B lym-
phocytes (CD19+/FITC). The CD4/CD8 and CD3/CD19
ratios were calculated as the percentage of CD4+ T cells di-
vided by the percentage CD8+ T cells and the percentage
of CD3+ T cells divided by the percentage CD19+ T cells.
Statistical analysis
Data are expressed as mean ± standard error. Compari-
sons of mortality were made by analyzing Kaplan-Meier
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survival curves and then log-rank test to assess for dif-
ferences in survival. Mann-Whitney U test was used to
evaluate the differences between groups. One-way ana-
lysis of variance followed by Tukey’s post-test was used
for analysis of multiple comparison groups. The num-
bers of samples per group (n) are specified in the figure
legends. Statistical significance was set at *P < 0.05,
**P < 0.01, and ***P < 0.001.
Results
All MSCs used in this study showed adherence to plas-
tic, expression of classic MSCs markers, and differenti-
ation to osteoblasts, adipocytes, and chondroblasts
(Additional file 1: Figure S1) in accordance with previ-
ously described criteria [19].
MenSCs exert anti-microbial activity mediated by the
secretion of hepcidin
In vitro assays were performed to evaluate the direct and
indirect anti-microbial MSC activity on bacterial growth.
Since the anti-bacterial properties of BMSCs are well
known, we decided to compare the anti-microbial effect
of MenSCs with respect to BMSCs to establish the com-
parative anti-microbial potency of MenSCs. For the dir-
ect assay, MSCs were incubated with a bacterial mixture
for 6 hours. As shown in Fig. 1a, both MenSCs and
BMSCs exerted a significant inhibition of the bacterial
growth in comparison with control (P ≤ 0.001). To deter-
mine whether this anti-bacterial effect is associated with
the secretion of soluble factors, CM was studied (indir-
ect assay) in accordance with published protocols [13].
Whereas both non-stimulated and stimulated CM exhib-
ited important anti-bacterial activity, MenSCs non-
stimulated CM showed a greater inhibition of bacterial
growth compared with BMSCs non-stimulated CM
(P ≤ 0.001) (Fig. 1b). This effect was enhanced when
CM was collected from MSCs previously stimulated
with a bacterial load prior to incubation for direct as-
says (P ≤ 0.001). Taken together, these data suggest
that inhibition of bacterial growth is associated with
the secretion of soluble factors by MSCs and that, at
least in in vitro conditions, MenSCs appear to be a
better cell candidate for control of bacterial growth
compared with BMSCs.
To better understand the anti-microbial activity exhib-
ited by MenSCs, we analyzed the expression of different
AMPs under basal conditions and after bacterial stimu-
lation. Levels of LL37 and β-defensin (hBD-1, -2, and -3)
could not be detected in MenSCs and BMSCs in either
non-stimulated or stimulated conditions (data not
shown). Interestingly, a low expression level of hepcidin
was detected in both cell sources. The bacterial stimula-
tion induced the increase of hepcidin expression up to
42- and 50-fold in BMSCs and MenSCs, respectively
(P ≤ 0.001) (Fig. 1c). Hypoxic culture conditions are
known to inhibit the expression of hepcidin in hepatoma
cells [23]. Therefore, MenSCs were cultured for 24 hours
in both normal and hypoxic conditions and in the pres-
ence or absence of the bacterial stimulus. Under hyp-
oxia, the expression of hepcidin decreased in both
conditions; however, statistical significance was obtained
only for the stimulated MenSCs (P ≤ 0.05), abrogating
the effect of bacterial stimulus on hepcidin expression
(Fig. 1d). Furthermore, the inhibition of hepcidin by the
hypoxic conditions entailed a loss of the anti-microbial
activity of MenSCs in comparison with normoxic condi-
tions (Fig. 1e).
MenSCs improve survival and multiorgan dysfunction in
the CLP-induced sepsis model
Because MenSCs showed higher bacterial inhibition po-
tential in vitro, their therapeutic effect in sepsis was eval-
uated by using a CLP-induced sepsis model (Additional
file 2: Figure S2). At 96 hours after different treatment, a
significant increase in the survival rate of MenSCs + AB
treatment group was observed in comparison with all
the other experimental groups (saline, P ≤ 0.0001; AB,
P = 0.0374; MenSCs, P = 0.0004) as shown in Fig. 2a.
The survival rate reached by MenSCs + AB group was
95 % (21/22), while survival in the saline, AB, and
MenSCs groups was 6 % (1/16), 73 % (16/22) and
48 % (11/21), respectively. Both conventional AB and
MenSCs treatments increased the survival of animals
compared with saline (P ≤ 0.002 and P ≤ 0.0002, re-
spectively). No differences were observed between AB
group compared with the MenSCs group.
Because sepsis lethality is associated with multiple
organ failure, biochemical indicators of hepatic, renal,
and pancreatic function were assessed in serum samples.
No differences were observed between the different
groups in the study with respect to renal functional pro-
file (serum creatinine and BUN levels) and pancreatic
functional marker (amylase levels) (data not shown).
However, liver function was markedly improved in ani-
mals that received MenSCs without or with AB (Fig. 2b).
The concentrations of the liver enzymes ALT and AST
were detected at lower values in the MenSCs (ALT
57.25 ± 8.107 U/l P ≤ 0.05; and AST 153.5 ± 5.299 U/l
P ≤ 0.05) and MenSCs + AB group (ALT 49.75 ± 2.428 U/l
P ≤ 0.01; and AST 182.3 ± 1.99 U/l P ≤ 0.05) compared
with the saline group (ALT 79.8 ± 5.083 U/l and AST
331.2 ± 49.29 U/l), suggesting that the protective or regen-
erative liver effect seems to be contributed mainly by the
MenSCs. Although no difference was found in the con-
centration of ALP enzyme, the analysis showed similar
concentrations between sham (47.67 ± 3.18 U/l), MenSCs
(48.75 ± 5.17 U/l), and MenSCs +AB (44.75 ± 5.45 U/l)
groups, in contrast to the increased levels observed in
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Fig. 1 MenSCs exert an important in vitro anti-microbial effect, which is associated in part with the increased expression of hepcidin. MenSCs and
BMSCs were evaluated in their capacity to inhibit bacterial proliferation. a Direct inhibition of the bacterial proliferation. Cells were cultured in
direct contact with a bacterial mixture. After 6 hours, the CM was collected and plated on blood-agar plates. Values are expressed as CFUs per
milliliter. b Indirect inhibition of bacterial proliferation. CM of cells cultured with or without bacterial stimulation was collected and their antimicrobial
activity was tested by the incubation with a bacterial mixture. Values are expressed as CFUs per milliliter. c Relative expression of hepcidin. The mRNA
expression levels of hepcidin under both basal and stimulated conditions are determined by qRT-PCR. d Inhibition of hepcidin by hypoxia. The mRNA
expression levels of hepcidin under normoxic and hypoxic culture conditions in basal and stimulated MenSCs are determined by qRT-PCR. e Direct
inhibition of the bacterial proliferation under hypoxic conditions. MenSCs were cultured in direct contact with a bacterial mixture under normoxic and
hypoxic conditions for 24 hours. After 24 hours, the CM was collected and plated on blood-agar plates. Values are expressed as CFUs per milliliter. Data
are presented as the mean ± standard error. BMSCs bone marrow-derived mesenchymal stem cells, CFU colony-forming unit, CM conditioned medium,
MenSCs menstrual derived mesenchymal stem cells, ns non-significant, qRT-PCR quantitative reverse transcription-polymerase chain reaction
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saline (90 ± 21.47 U/l) and AB (74.25 ± 12.03 U/l) groups
(Additional file 3: Figure S3). Altered blood glucose
concentration is commonly observed in sepsis and is as-
sociated with adverse outcome [24]. Decreased serum
albumin levels are associated with acute-phase response
of the liver [25, 26] and an increased capillary leakage
[27, 28]. After MenSCs + AB treatment, we observed a
normalization in the blood glucose and albumin levels,
indicating a recovery in the organ-wide metabolic fail-
ure. Specifically, animals from the MenSCs + AB group
(3.475 ± 0.6787 U/l) exhibited levels similar to animals
from the sham group (5.433 ± 0.088 U/l), but animals
from the saline (2.44 ± 0.45 U/l), AB (2.55 ± 0.31 U/l)
and MenSCs (3.175 ± 0.35 U/l) groups had a decrease in
serum glucose concentration (Fig. 2b). The levels of
serum albumin demonstrated a reduction in the saline
group (2.440 ± 0.4490 g/dl) compared with the sham
group (5.433 ± 0.088 g/dl P ≤ 0.01), but an upward ten-
dency was observed in groups of animals that received
cells (Additional file 3: Figure S3).
Although the histological examination of kidney and
liver at 40 hours post-surgery showed no significant dif-
ferences among groups (data not shown), consistently
with other reports [5, 29] lung histology assessment re-
vealed that MSCs treatment effectively prevented acute
lung injury (Fig. 2c). In lungs of animals from the saline
group, vast areas of atelectasis were observed with
marked venular and capillary congestion with reduced
Fig. 2 Treatment with MenSCs alone or in combination with antibiotics improves survival and protects against multiorgan dysfunction in
CLP-induced sepsis. a Survival curves in mice with polymicrobial sepsis and different treatments. C57BL6/J mice subjected to CLP-induced sepsis
were randomized into five groups: sham (n = 12), saline (n = 16), antibiotics (AB) (n = 22), MenSCs (n = 21), and MenSCs + AB (n = 22). Three hours
post-surgery, mice were injected with saline (vehicle), AB and/or MenSCs. Survival percentages of untreated and treated mice after CLP are
presented as a Kaplan-Meier survival curve. b Serum concentration of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and
glucose after CLP-induced sepsis. Serum was isolated 24 hours post-surgery and treatment administration (sham, n = 3; saline, n = 5; AB, n = 4;
MenSCs, n = 4; MenSCs + AB, n = 4), and the concentrations of biomarkers of liver function and total glucose were determined. Dot plots represent
individual values, horizontal bars represent mean values, and vertical bars represent standard error values. c Lung histology after
CLP-induced sepsis. At 40 hours post-surgery and treatment infusion, lungs were collected, fixed, embedded in paraffin, and stained with
hematoxylin-eosin. Pictures are representative images of lungs from the different experimental groups. AB antibiotics, CLP cecal ligation
puncture, MenSCs menstrual derived mesenchymal stem cells
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airspaces and a moderate amount of septal leucocytes.
In contrast, in all treated groups, the lungs showed
irregular distended alveoli and isolated areas of atel-
ectasis with moderate capillary congestion, irregular
alveolar distension, and normal amounts of septal
leukocytes.
MenSC treatment downregulates the inflammatory
responses in vivo
To determine the effect of MenSCs on the immune re-
sponse to infection, serum TNF-α, IL-6, MCP-1, and IL-
10 were determined. Whereas at 24 hours post-CLP no
differences in the serum levels of cytokines were de-
tected, at 40 hours a clear modulation of the inflamma-
tory response was observed in treated animals (Fig. 3).
Specifically, a reduction in the TNF-α and MCP-1 serum
concentration was observed in the MenSCs with and
without AB groups in comparison with the saline group
(P ≤ 0.05) (Fig. 3a, b). Also, IL-6 serum levels were de-
creased in the AB, MenSCs, and MenSCs + AB groups
in comparison with the saline group (P ≤ 0.05) (Fig. 3c).
Antibiotic and MenSCs groups showed a reduction in
the levels of IL-10 in comparison with untreated mice
(P ≤ 0.05) (Fig. 3d). Taken together, our data suggest that
while animals receiving treatment showed modulation of
the innate immune response, only groups where
MenSCs without or with AB presented a significant re-
duction in pro- and anti-inflammatory cytokines, sug-
gesting that MenSCs can effectively rescue mice from
the uncontrolled systemic inflammatory response after
CLP-induced sepsis.
With the progression of sepsis, the adaptive immune
system reduces their efficiency by an increase in anti-
inflammatory mediators and loss of T and B cells via
apoptosis [30, 31]. At 24 hours, increases of the distribu-
tion of CD45+ CD3+ CD8+ and CD4+/CD8+ were ob-
served in the MenSCs group in comparison with the
saline group (P ≤ 0.05); however, at 40 hours, no differ-
ences were detected between the experimental groups
(Additional file 4: Figure S4). In CD45+ CD3+ cell popu-
lations, no difference between groups was detected at 24
and 40 hours post-CLP. However, a reduction in circu-
lating CD45+ CD19+ lymphocytes was observed at
24 hours in treated (P ≤ 0.05; P ≤ 0.001) and non-treated
(P ≤ 0.001) groups, showing an important recovery ex-
clusively in treated animals at 40 hours, reaching a sig-
nificant increase in the MenSCs + AB group (P ≤ 0.01)
(Fig. 4a) in comparison with untreated animals. In con-
sequence, a reduction was also observed in the CD45+
CD3+/CD45+ CD19+ ratio in cell-treated groups in com-
parison with the untreated group (P ≤ 0.05). Representa-
tive dot plots of the specific lymphocyte subsets at
40 hours after sepsis induction and administration of dif-
ferent treatments are shown in Fig. 4b. Altogether, no
significant loss of T and B lymphocytes was observed in
all treated groups, suggesting that MenSCs can effect-
ively modulate the immune response in animals with




























































































Fig. 3 MenSCs modulate the response of the host immune system to sepsis. At 24 and 40 hours after CLP-induced sepsis and treatment
administration, blood samples were obtained to determine the serum concentration of the inflammatory cytokines (a) TNF-α, (b) MCP-1,
(c) IL-6, and (d) IL-10 using a Cytometric Bead Array and analyzed by flow cytometry (sham, n = 6; saline, n = 3–11; AB, n = 4–6; MenSCs,
n = 5–6; MenSCs + AB, n = 6). Histograms represent the mean ± standard error. AB antibiotics, CLP cecal ligation and puncture, IL interleukin,
MCP-1 monocyte chemoattractant protein-1, MenSC menstrual derived mesenchymal stem cells, ns non-significant, TNF-α tumor
necrosis factor-alpha
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MenSC treatment results in significant bacterial clearance
in septic mice
As another measure of the beneficial effect of MenSCs
against infection, bacterial clearance was assessed in the
blood, peritoneal fluids, and spleen of treated animals.
At 24 hours post-CLP, animals that received MenSC
treatment alone or in combination with antibiotics
showed a lower bacterial load in blood compared with
the untreated group (P ≤ 0.05) (Fig. 5a), reaching values
similar to those of the sham group (MenSCs 0.2 ±
0.2 CFU/ml; MenSCs + AB 0.17 ± 0.17 CFU/ml; and
sham 0.17 ± 0.17 CFU/ml). In peritoneal lavage, adminis-
tration of AB alone or in combination with MenSCs de-
creased CFU counts in comparison with the saline
group (P ≤ 0.05) (Fig. 5b). In contrast, no differences in
spleen were observed among different treatment groups
(Fig. 5c). Altogether, the results suggest that antibiotics
seem to contribute in the control of the bacterial growth
in local sepsis (abdominal cavity) but that MenSCs ap-
pear to suppress the systemic bacterial proliferation.
(A)
(B)


































































Fig. 4 MenSCs in combination with antibiotics prevent the decrease of CD45+ CD3+ and CD45+ CD19+ lymphocyte levels after CLP-induced
sepsis. Blood samples were obtained 24 and 40 hours after administration of various treatments post-CLP, and specific lymphocyte subsets were
determined by fluorescence-activated cell sorting. a Graphs represent the percentage of CD45+ CD3+ and CD45+ CD19+ lymphocytes and the
ratio CD45+ CD3+/CD45+ CD19 (sham, n = 3–6; saline, n = 3–10; AB, n = 3–6; MenSCs, n = 3–6; MenSCs + AB, n = 3–6). Histograms represent the
mean ± standard error. b Representative dot plots of specific lymphocyte subsets described in (a) at 40 hours post-induction of sepsis and administration
of different treatments. AB antibiotics, CLP cecal ligation and puncture, LB B lymphocytes, LT T lymphocytes, MenSCs menstrual derived mesenchymal































































































































Fig. 5 MenSCs alone or in combination with antibiotic treatment promote bacterial clearance in CLP-induced sepsis in mice. Blood, peritoneal
fluid, and spleen were obtained 24 hours after administration of the different treatments (sham, n = 6; saline, n = 11; AB, n = 6; MenSCs, n = 5;
MenSCs + AB, n = 6). Bacterial loads were determined after incubating at 37 °C overnight and are expressed as CFUs per milliliter. a Bacterial load
in blood. b Bacterial load in peritoneal fluid. c Bacterial load in spleen. Data are presented as mean ± standard error. AB antibiotics, CFU colony-forming
unit, CLP cecal ligation and puncture, MenSCs menstrual derived mesenchymal stem cells, ns non-significant
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Septic mice display a higher retention of MenSCs in the
peritoneal cavity
To assess the fate in the peritoneal cavity of the CLP
mice, MenSCs were labeled with PKH-26 (Fig. 6a) and
injected intraperitoneally in healthy and sepsis-induced
mice. After 24 hours post-injection, the spleen, heart,
kidneys, lungs, liver, and peritoneal fluid were collected
to detect labeled cells by flow cytometry analysis. Al-
though no labeled MenSCs were detected in the differ-
ent analyzed organs, the injection site contained
detectable levels of PKH-26+ cells. Furthermore, septic
mice showed a fourfold increase in the retention of
injected MenSCs in the peritoneal cavity in comparison
with healthy control mice (Fig. 6b).
Conditioned media from MenSCs improve survival and
multiorgan dysfunction in the CLP-induced sepsis model
Multiple published reports have revealed that secretion
of a broad range of bioactive molecules is behind the
therapeutic benefits of MSCs in sepsis. In this context
and in line with the marked inhibition of bacterial
growth observed in vitro (Fig. 1), we decided to evaluate
the in vivo therapeutic effect of the paracrine factors se-
creted by MenSCs in the CLP-induced sepsis model
(Fig. 7). Notably, at 96 hours post-sepsis induction,
MenSCs CM without or with AB increased survival
compared with saline group (P < 0.0001). The MenSC
CM+AB group exhibited a larger increase in survival
than that where MenSC CM was administered alone
with survival rates of 55 % (12/22) and 25 % (4/16), re-
spectively (P = 0.0462). Interestingly, although the im-
provement in survival of the MenSCs CM+AB
treatment group matched that observed in the MenSCs
treatment group, it did not surpass that of the MenSCs
+ AB treatment.
Discussion
MenSCs are a fully characterized multipotent stromal
cell population [19, 32] that has shown several regenera-
tive properties in different preclinical animal models
[33–36]. In sepsis, the use of MSCs to combat the sys-
temic infection [14] or modulate the response of the
host immune system to the disease [3, 10] has been
studied previously, showing that MSCs might be benefi-
cial in sepsis treatment when infused at the disease
onset. Because patients with sepsis show a fast deterior-
ation of a patient’s condition in the first few hours of on-
set, an MSCs treatment might be administered with an
identical promptness [37]. In this context, MenSCs
present some advantages over MSCs derived from other
sources, such as the high frequency of mesenchymal






































































Fig. 6 Septic mice show higher retention of the injected MenSCs in the peritoneal cavity in comparison with healthy control mice. MenSCs were
labelled with PKH-26 and analyzed by flow cytometry. a Fluorescence-activated cell sorting plot showing a 95 % labelling efficiency. Around 2 × 106 cells
were injected intraperitoneally in septic or healthy mice. b Histogram and representative flow cytometry plots showing the percentage of remaining
cells in peritoneal lavage at 24 hours post-injection. CLP cecal ligation puncture, MenSCs menstrual derived mesenchymal stem cells
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clinical-scale allogeneic transplantation in less time.
Allogeneic MSCs therapy is regarded as a preferred
source for treatments because it allows a cell infusion
with a ready-to-use and off-the-shelf product in acute
life-threatening indications such as sepsis, in which iso-
lation and expansion of autologous MSCs are not op-
tions [38]. In the study presented here, we demonstrate
that MenSCs in synergy with antibiotics can beneficially
alleviate sepsis-associated symptoms and improve
survival.
In the in vitro comparative study, we demonstrate that
MenSCs exert an important anti-microbial effect, both
directly and through factors present in its CM. In con-
trast with the previously published data, in which ex-
pression of the antimicrobial peptide LL-37 was detected
following stimulation with Escherichia coli [13], we did
not observe any basal or stimulated expression of this
gene under both bacterial mixture and LPS stimulations
(data not shown). On the other hand, we observed an el-
evated mRNA expression of the AMP-hepcidin after a
polybacterial stimulation. Hepcidin, a peptide hormone
synthesized mainly in the liver, is the principal regulator
of systemic iron homeostasis that has been detected in
high levels during infections and inflammation [38, 39].
To further understand the implication of hepcidin in the
observed antibacterial effect, its expression was down-
regulated through hypoxic culture. In fact, it has been
reported that hypoxia inhibited the hepcidin expression
in different cell types via decreased SMAD4 signaling
pathway [23, 39, 40]. We first show that hepcidin ex-
pression in MenSCs is suppressed in hypoxia. The inhib-
ition of hepcidin results in the loss of the antimicrobial
property of MenSCs, suggesting a hepcidin-dependent
mechanism. Moreover, it has been demonstrated that
hepatic hepcidin knockdown mice displayed a decreased
bacterial clearance, increased mortality, exacerbated
organ damage, and a compromised host inflammatory re-
sponse following sepsis induction [40]. To our knowledge,
these results provide, for the first time, evidence of hepci-
din expression in MSCs and their implication in the anti-
microbial effect. However, further investigation is required
to look at the pathophysiological levels of hepcidin in the
menstrual fluid following intra-uterine infections and also
the effect of their dysregulation in this context.
In the study involving an in vivo animal model,
MenSCs were capable of reducing animal mortality
regulating different traits of sepsis, such as the organ
dysfunction, modulation of the inflammatory response
without severe immunosuppression, and promotion of
bacterial clearance, to a degree similar to that of the
standard clinical sepsis treatment (antibiotic therapy).
Notably, the synergism between MenSCs + AB resulted
in the highest amelioration of the survival animal pro-
portion, indicating that the arrival of the MenSCs to the
clinic should be in combination with the current therapy
of sepsis. Paracrine factors have been postulated as a
mechanism in the regeneration/protection of tissues in
lung injury and inflammation [41], acute myocardial in-
farction [42, 43], and sepsis [3, 5]. In this context, we
further investigated the effect of the soluble antimicro-
bial and other tissue protective factors secreted by
MenSCs by treating animals with its CM. Although the
experimental results showed prolonged survival in mice
infused with MenSCs CM in comparison with the un-
treated group, the improvement did not match the level
of survival observed in the MenSCs treated groups. This
suggests that although the CM had a beneficial effect,
the presence of cells in the inflammatory and infectious
context is necessary to achieve the important therapeutic
effect obtained. Indeed, it is well known that many
MSC-expressed factors can be activated in response to
stress or specific stimulation, similar to hepcidin expres-
sion following microbial stimulation. Although it is
interesting to test the effect of pre-activated cells or
stimulated CM in future experimental plans, the dose
(low, medium, or high), frequency (one or multiple), and
Fig. 7 MenSCs CM improves the survival in CLP-induced sepsis in mice. C57BL6/J mice with CLP-induced sepsis were randomized in five groups:
sham (n = 12), saline (n = 16), antibiotics (AB) (n = 22), MenSCs CM (n = 16), and MenSC CM + AB (n = 22). After 3 hours post-sepsis induction, mice
were injected with saline (vehicle), AB and/or MenSC CM. Survival percentages of untreated and treated mice are represented as a Kaplan-Meier
survival curve. AB antibiotics, CFU colony-forming unit, CLP cecal ligation and puncture, CM conditioned medium, MenSCs menstrual derived
mesenchymal stem cells
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the time of administration (early or late) of the infusion
should be defined as well.
While the present results provide a new source and
evidence regarding the therapeutic effect of allogeneic
MSCs in sepsis, significant advances are required to fully
understand the multiple mechanisms of action behind
the cell-based therapy. In addition, there are significant
limitations that need to be addressed, taking into consid-
eration the narrow time frame for the treatment of sepsis,
where ready-to-inject dose of cells needs to be available.
Conclusions
The combination of the in vitro and in vivo experiments
obtained here shows that MenSCs can alleviate sepsis-
associated symptoms. The mechanisms by which MenSCs
improve survival are likely to be due to the collective ef-
fects of their antimicrobial and immunomodulatory prop-
erties and tissue regenerative factors expressed by these
cells. Moreover, MenSCs in synergy with the antibiotic
treatment markedly improved survival in CLP-induced
sepsis, suggesting that the synergy between MenSCs and
antibiotics improves the sepsis outcome by acting on mul-
tiple targets. It is important to note that the implications
of the present findings are not exclusively limited to sep-
sis, as the observed synergy could also potentiate the indi-
vidual effect of each component in a number of other
bacterial infections and subsequently play a pivotal role in
the field of infectious diseases.
Additional files
Additional file 1: Figure S1. Characterization of MenSCs and BMSCs.
Stem cells isolated from the menstrual fluid and bone marrow were
characterized according to International Society for Cellular Therapy
guidelines. a MenSCs and BMSCs showed stem cell-like immunophenotypic
markers. Fluorescence-activated cell sorting profile of representative cell
samples. Blue and orange filled histograms denote the fluorescent profile of
the indicated antigens in MenSCs and BMSCs, respectively; red histograms
correspond to isotype-matched controls. b MenSCs and BMSCs displayed
mesodermal differentiation. Tri-lineage differentiation of representative
MenSCs and BMSC samples. Cells were cultured with adipogenic, osteo-
genic, and chondrogenic induction media for 14–21 days and then stained
with Oil Red O, Alizarin Red, and Safranin O staining, respectively. Scale bar:
200 μm. BMSCs bone marrow-derived mesenchymal stem cells,MenSCs
menstrual derived mesenchymal stem cells. (PDF 489 kb)
Additional file 2: Figure S2. Experimental design for the in vivo
studies. Diagram of the experimental design of (a) survival studies and
(b) therapeutic effects studies of MenSC administration in mice with
CLP-induced sepsis. AB antibiotics, CFU colony-forming unit, CLP cecal
ligation and puncture, CM conditioned medium, H&E hematoxylin and
eosin, MenSCs menstrual derived mesenchymal stem cells. (PDF 370 kb)
Additional file 3: Figure S3. Effect of MenSCs treatment in mice with
polymicrobial sepsis. Serum was isolated 24 hours after sepsis induction
and administration of different treatments with AB or MenSCs or both
(sham, n = 3; saline, n = 5; AB, n = 2–4; MenSCs, n = 4; MenSCs + AB, n = 4)
to determine the concentrations of alkaline phosphatase (ALP) (left panel)
and albumin (right panel). Dot plots represent individual values, horizontal
bars represent mean values, and vertical bars represent standard error
values. **P ≤ 0.01. AB antibiotics, MenSCs menstrual derived mesenchymal
stem cells, ns not significant. (PDF 180 kb)
Additional file 4: Figure S4. Effect of MenSCs treatment on CD4+ and
CD8+ lymphocytes in mice with polymicrobial sepsis. Blood samples were
obtained at different time points after induction of sepsis and
administration of various treatments to determine specific lymphocyte
subsets using flow cytometry (sham, n = 3–5; saline, n = 3–10; AB, n = 3–6;
MenSCs, n = 3–6; MenSCs + AB, n = 3–5). Graphs show the percentages of
CD45+ CD3+ CD4+ and CD45+ CD3+ CD8+ lymphocytes and the ratios of
CD4+/CD8+ at (a) 24 hours and (b) 40 hours in untreated and treated
mice. Dot plots represent individual values, horizontal bars represent
mean values, and vertical bars represent standard error values. *P ≤ 0.05.
AB antibiotics, MenSCs menstrual derived mesenchymal stem cells, ns not
significant. (PDF 238 kb)
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